Mifegyne

Mifepristone, the active ingredient in Mifegyne, is a progesterone receptor antagonist presented as a 200 mg tablet for oral use. It blocks progesterone activity, enabling medical termination of early pregnancy and is also employed in the management of Cushing’s syndrome and symptomatic uterine fibroids in adult patients.

GNH USA supplies Mifegyne as a licensed, GDP‑compliant product sourced from the European Union, providing reliable access to hospitals, pharmacies and clinics worldwide through its international distribution network. The company adheres to stringent quality standards and supports regulatory compliance for its clients.

Mifegyne (mifepristone) acts as a progesterone receptor antagonist and is used in specific reproductive and endocrine conditions.

Medical termination of pregnancy (up to 9 weeks gestation): blocks progesterone receptors, leading to decidual breakdown and, when followed by misoprostol, results in uterine evacuation. Cushing's syndrome: antagonizes progesterone‑mediated pathways that contribute to cortisol excess, thereby lowering serum cortisol levels in patients with endogenous hypercortisolism. Uterine fibroids: inhibits progesterone‑driven fibroid growth, helping to reduce fibroid volume and control abnormal uterine bleeding in eligible women.

Mifegyne may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Bleeding: vaginal spotting or heavier bleeding after administration. - Nausea: mild to moderate nausea. - Abdominal cramping: uterine cramping or pain. - Diarrhea: loose stools or gastrointestinal upset.

Serious or Rare Side Effects: - Severe infection: risk of sepsis if retained products remain. - Excessive hemorrhage: heavy bleeding requiring medical intervention. - Allergic reaction: rash, urticaria, or anaphylaxis.

Prior to prescribing Mifegyne, clinicians should evaluate several safety considerations. - Gestational age assessment: confirm pregnancy is ≤9 weeks by ultrasound. - Contraindications: avoid in ectopic pregnancy, chronic adrenal failure, or anticoagulant therapy. - Cardiovascular status: monitor patients with hypertension or cardiac disease. - Infection risk: assess for pelvic infection before use. - Follow‑up care: arrange clinical review after medication to confirm complete evacuation. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Mifegyne can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce mifepristone plasma levels. - Anticoagulants (e.g., warfarin): increased risk of bleeding when combined with mifepristone‑induced uterine bleeding.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase mifepristone exposure. - Glucocorticoids: may blunt the cortisol‑lowering effect in Cushing’s syndrome. - Misoprostol: required for complete abortion, dosing must be coordinated.